CJC-1295 and Ipamorelin form one of the most extensively studied growth hormone secretagogue combinations in peptide research. Here is the mechanism, the data, and what distinguishes the DAC and no-DAC variants.
New data presented at the 2026 ADA Scientific Sessions sharpens the picture on lean mass loss during GLP-1 therapy and what countermeasures researchers are exploring.
A first-of-its-kind head-to-head clinical trial is directly comparing tirzepatide and retatrutide in adults with obesity. Here is what researchers need to know about TRIUMPH-5 and what the data shows so far.
A complete visual reference guide to 50+ research peptides from FenaLife Labs, organized by category with mechanism of action, primary research areas, and documented dosage ranges.
The FDA’s regulatory stance on research peptides is evolving in 2026, with an advisory panel scheduled to review several compounds. Here is what the current landscape looks like for researchers and suppliers.
Ipamorelin is a selective growth hormone secretagogue peptide studied for its effects on GH release, body composition, and metabolic research. This guide covers what it is, how it works, and what the research shows.
BPC-157 is a synthetic pentadecapeptide derived from gastric mucosa studied for its effects on tissue repair, angiogenesis, and nitric oxide signaling. Here is what the research shows about how it works.
Tirzepatide is a first-in-class dual GIP and GLP-1 receptor agonist studied in metabolic, cardiovascular, and body composition research. Here is what the science shows.
Tirzepatide and Semaglutide are both GLP-1-based research peptides, but their mechanisms differ significantly. This comparison breaks down what makes each compound unique in research models.
Semaglutide is a GLP-1 receptor agonist studied for its role in glucose metabolism, appetite regulation, and cardiovascular research. This guide breaks down its mechanism of action.
